SpringerLink
Log in

Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

MicroRNA-210 (miR-210) plays important roles in the regulation of cell growth, angiogenesis, and apoptosis in different cancer type. Previous study of miRNA expression profiling found that miR-210 was significantly elevated in osteosarcoma samples. However, its roles in this disease have not been fully elucidated. Thus, the aim of this study was to investigate the association of miR-210 expression with clinicopathologic features and prognosis in patients with osteosarcomas. Quantitative real-time reverse transcriptase-polymerase chain reaction analysis was performed to detect the expression level of miR-210 in cancerous and noncancerous bone tissues from 92 children treated for primary osteosarcomas. MiR-210 expression was significantly increased in osteosarcoma tissues compared with that in corresponding noncancerous bone tissues (P < 0.001). In addition, miR-210 upregulation more frequently occurred in osteosarcoma tissues with large tumor size (P = 0.02), poor response to preoperative chemotherapy (P = 0.008), and positive metastasis (P = 0.01). Moreover, miR-210 upregulation was associated with significantly decreased overall survival (P = 0.007) and progression-free survival (P = 0.01). In the Cox proportional hazard model, it was confirmed that its expression in the biopsy samples was an independent prognostic factor of unfavorable survival in osteosarcoma (for overall survival: P = 0.01; for progression-free survival: P = 0.02). These findings suggested that miR-210 upregulation showed a strong correlation with tumor aggressive progression of pediatric osteosarcoma and could help prognostic screening of patients with this malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011;2011:959248.

    Article  PubMed  Google Scholar 

  2. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.

    Article  PubMed  Google Scholar 

  3. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 2011;28:493–503.

    Article  PubMed  CAS  Google Scholar 

  4. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–18.

    PubMed  Google Scholar 

  5. Osman A. MicroRNAs in health and disease–basic science and clinical applications. Clin Lab. 2012;58:393–402.

    PubMed  CAS  Google Scholar 

  6. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13:e249–58.

    Article  PubMed  CAS  Google Scholar 

  7. Subramanian S, Kartha RV. MicroRNA-mediated gene regulations in human sarcomas. Cell Mol Life Sci. 2012;69:3571–85.

    Article  PubMed  CAS  Google Scholar 

  8. Lulla RR, Costa FF, Bischof JM, Chou PM. de F Bonaldo M, Vanin EF, Soares MB. Identification of Differentially Expressed MicroRNAs in Osteosarcoma. Sarcoma. 2011;2011:732690.

    Article  PubMed  Google Scholar 

  9. Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, Kulshreshtha R, Banfi C, Stubbs A, Calin GA, Ivan M, Capogrossi MC, Martelli F. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 2009;284:35134–43.

    Article  PubMed  CAS  Google Scholar 

  10. Mizuno Y, Tokuzawa Y, Ninomiya Y, Yagi K, Yatsuka-Kanesaki Y, Suda T, Fukuda T, Katagiri T, Kondoh Y, Amemiya T, Tashiro H, Okazaki Y. miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. FEBS Lett. 2009;583:2263–8.

    Article  PubMed  CAS  Google Scholar 

  11. Huvos AG. Osteosarcoma in adolescents and young adults: new developments and controversies. Commentary on pathology. Cancer Treat Res. 1993;62:375–7.

    Article  PubMed  CAS  Google Scholar 

  12. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    Article  PubMed  CAS  Google Scholar 

  13. Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3:e47.

    Article  PubMed  Google Scholar 

  14. Hong L, Han Y, Zhang H, Zhao Q, Qiao Y. miR-210: a therapeutic target in cancer. Expert Opin Ther Targets. 2013;17:21–8.

    Article  PubMed  CAS  Google Scholar 

  15. He J, Wu J, Xu N, **e W, Li M, Li J, Jiang Y, Yang BB, Zhang Y. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res. 2012 In press.

  16. Merlo A, de Quiros SB, Secades P, Zambrano I, Balbín M, Astudillo A, Scola B, Arístegui M, Suarez C, Chiara MD. Identification of a Signaling Axis HIF-1α/MicroRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas. J Clin Endocrinol Metab. 2012;97:E2194–200.

    Article  PubMed  CAS  Google Scholar 

  17. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G, Voros D. Expression of MicroRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2012 In press.

  18. Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene. 2012;507:135–8.

    Article  PubMed  CAS  Google Scholar 

  19. Võsa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-analysis of microrna expression in lung cancer. Int J Cancer. 2012 In press.

  20. Wotschofsky Z, Busch J, Jung M, Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller K, Kristiansen G, Erbersdobler A, Jung K. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin Chim Acta. 2012 In press.

  21. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res. 2009;2:807–13.

    Article  CAS  Google Scholar 

  22. Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE. 2011;6:e20980.

    Article  PubMed  Google Scholar 

  23. Greither T, Würl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschläger C, Holzhausen HJ, Wach S, Eckert AW, Taubert H. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer. 2012;130:1230–5.

    Article  PubMed  CAS  Google Scholar 

  24. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010;116:2148–58.

    PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Pediatric Orthopedic Department, Shanghai Children’s Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200031, China

    Haiqing Cai & Zhigang Wang

  2. Orthopedics Department, Zhujiang Hospital, The Southern Medical University, Guangzhou, 510282, China

    Lijun Lin

  3. Orthopaedics Department, Xuhui central hospital, Shanghai, 200031, China

    Haikang Cai

  4. Orthopaedics Department, Shanghai Sixth People’s Hospital, Shanghai Institute for Microsurgery of Extremities, Shanghai Jiaotong University, Shanghai, 200031, China

    Mingjie Tang

Authors
  1. Haiqing Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lijun Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haikang Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mingjie Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhigang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhigang Wang.

Additional information

Haiqing Cai and Lijun Lin contribute equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cai, H., Lin, L., Cai, H. et al. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol 30, 499 (2013). https://doi.org/10.1007/s12032-013-0499-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0499-6

Keywords

Search

Navigation